CBIO
Crescent Biopharma, Inc.
$17.03
+0.07 (+0.41%)
At close · Jul 7
Market Cap
$463.48M
Shares
27,571,935
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$17.03
Open$16.90
Day$16.55–17.36
52W$8.72–27.41
Avg vol 30d342K
Short int3.3M · 12.1% float · 15.8d
Short vol76%
Last earningsMay 26, 2026
DataJan 2020–Jul 2026
Filing10-Q · Apr 29
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+17%
above
Price vs 50-day avg
−10%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
44%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−5%
trailing
6-month return
+55%
trailing
YTD return
+44%
this year
Relative strength
+48%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $19 › 200d $15 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +17 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.14% of float · ▲ +2.7% MoM · 15.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
60 holders — near 1-yr high, broad support
Squeeze score
87
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
−2%
Y/Y
Free cash flow
$-72.5M
Balance sheet
$213.2M
net cash
Quant / Vol
risk profile
Volatility
79%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
8.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 28, 2026
Est · unconfirmed
· in 7 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Apr 29, 2026
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+17%
Bullish
Price vs 50-day avg
−10%
Bearish
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
44%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $19 › 200d $15 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +17 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.14% of float · ▲ +2.7% MoM · 15.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
60 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $9
Now $17 · 44%
52-wk high $27
vs 200-day avg +17%
vs 50-day avg -10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CBIO
this stock
Crescent Biopharma, Inc.
|
$463.48M | +43.6% | -99.9% | — | 12.1% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CBIO | -5.4% | -5.4% | +55.1% | -5.4% | +43.6% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | -6.3% | -6.8% | +47.5% | -5.5% | +33.9% |